|| List of recent Epithelial-related patents
| Systems and methods for reducing mucin hypersecretion|
Device methods and systems for ablating a mucosal surface to treat patients with mucin hypersecretion is disclosed. An ablation device having a balloon membrane with a plurality of electrodes arranged on an external surface thereof is disclosed.
| Frictional trans-epithelial tissue disruption collection apparatus and method of inducing an immune response|
In an embodiment of the invention, a frictional tissue sampling device with a head designed to be rotated without rotating off the designated site can be used to obtain tissue biopsy samples. A frictional tissue sampling device with a head designed to be rotated without rotating off the designated site can be used to obtain an epithelial tissue biopsy sample from lesions.
| Human epithelial cell line for 3-d modelizing of cancer and treatment thereof|
A cellular model is described that targets dysregulation or inappropriate activation of the sonic hedgehog/patched (shh/ptch) pathway. Also described, is a screening method using this cellular model to screen for pharmacological compounds that can treat or prevent skin cancer, in particular, basal cell carcinoma (bcc) lesions..
| Phosphaplatins as neuroprotective agents|
The present disclosure provides for compositions for the treatment of neurodegenerative diseases comprising one or more isolated phosphate complexes of platinum and methods of uses thereof for treating neurodegenerative diseases including amyotrophic lateral sclerosis, alzheimer's disease, stroke, epilepsy, parkinsons, huntington's disease and diabetes associated peripheral neuropathy the present disclosure is also directed towards an anti-angiogenic composition useful for inhibiting angiogenesis related to age-related macular degeneration, diabetic retinopathy and tumor-associated angiogenesis. An embodiment of the present disclosure is also directed towards a method for modulating the expression of pigment epithelial derived factor (pedf) gene in an individual in need thereof.
| Free ngal as a biomarker for cancer|
Uncomplexed neutrophil gelatinase associated lipocalin (ngal) is present at increased levels in individuals with atypical ductal hyperplasia (adh), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed ngal levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer..
| Antibody for detecting epithelial ovarian cancer marker and method for diagnosing epithelial ovarian cancer|
It is intended to find a highly specific epithelial ovarian cancer marker and to provide an antibody capable of specifically recognizing and detecting the marker or a fragment of the antibody. The present invention provides an anti-β1,6-n-acetylglucosaminyltransferase 5b antibody for diagnosis of epithelial ovarian cancer, i.e., an antibody for detection of a glycosyltransferase β1,6-n-acetylglucosaminyltransferase 5b as an epithelial ovarian cancer marker.
| Contact lenses|
The invention provides silicone hydrogel contact lenses that exhibit reduced back surface debris and reduced incidence of superior epithelial arcurate lesions.. .
|Patient stratification and determining clinical outcome for cancer patients|
In a first aspect the present invention is directed to a method of generating a scheme allowing classification of a cancer of an individual patient for estimating a clinical outcome for said patient. It also refers to a method of estimating a clinical outcome of a patient suffering from epithelial ovarian cancer (eoc).
|Laser-assisted epithelial removal|
In certain embodiments, a device configured to perform epithelial removal comprises a laser device and a control computer. The laser device can separate the epithelium from the bowman's layer of an eye using pulsed laser radiation having ultrashort pulses.
|Viruses lacking epithelial cell receptor entry|
The document provides nucleic acids, polypeptides, and viruses containing nucleic acids and/or polypeptides. The document also provides methods for using viruses to treat cancer patients.
|Scfv antibodies which pass epithelial and/or endothelial layers|
Scfv antibodies which specifically bind selected antigens and are obtainable by a method comprising (i) selecting from a pool of soluble and stable antibody frameworks a soluble and stable framework matching best the framework of a non-human antibody against the antigen with a certain binding specificity, (ii) either providing said soluble and stable framework with cdrs that bind specifically to said antigen, or mutating the framework of said non-human antibody towards the sequence of said soluble and stable framework, to generate scfv antibodies, (iii) testing the generated antibody for solubility and stability, and testing the generated antibody for antigen binding, and (iv) selecting an scfv that is soluble, stable and binds to the antigen specifically. Also provided are pharmaceutical compositions comprising said scfv antibody, methods of treatment and diagnosis for diseases related to over expression of antigens that are specifically bound by said antibody..
|Targeted buccal delivery of agents|
A delivery device for topical and systemic delivery of agents to targeted oral locations, such as mouth cancer cells, has been developed. The formulation includes a mucoadhesive polymeric matrix such as chitosan, which contains one or more therapeutic and/or diagnostic agents, taste masking agents, permeation enhancers, the therapeutic or diagnostic agent to be delivered, and a hydrophilic polymeric coating such as polyethyleneglycol (“peg”).
|Inhibitor for corneal epithelial cell death, inhibitor characterized by combining hyaluronic acid and flavin adenine dinucleotide|
A combination of hyaluronic acid or a salt thereof and flavin adenine dinucleotide or a salt thereof can be an inhibitor for corneal epithelial cell death induced by ultraviolet irradiation and/or dryness because it significantly inhibits the decline of the number of living cells in corneal epithelial cells induced by ultraviolet irradiation or dryness.. .
|Heterocyclic compounds, medicaments containing said compounds, use thereof and processes for the preparation thereof|
And the tautomers and the salts thereof, particularly the pharmaceutically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on epithelial sodium channels, and the use thereof for the treatment of diseases, particularly diseases of the lungs and airways.. .
|Method to estimate age of individual based on epigenetic markers in biological sample|
The invention provides methods and materials that use observation of dna characteristics to obtain information relating to the age of individuals. The instant disclosure identifies 88 sites in or near 80 genes for which the degree of cytosine methylation in epithelial and/or white blood cells is significantly correlated with age.
|Annexin a2 as immunological target|
Annexina2 (anxa2), a member of the annexin family of calcium-dependent, phospholipid binding proteins, is one of a panel of identified antigens recognized by the post-vaccination sera of patients who demonstrated prolonged disease-free survival following multiple vaccinations. Annexina2 is abundantly expressed in pancreatic adenocarcinomas and cell surface/membrane annexina2 increases with the progression from premalignant lesions to invasive pancreatic adenocarcinomas.
|Use of omega fatty acids for treating disease|
Eicosapentaenoic acid (epa) and docosahexaenoic acid (dha), or a salt or an ester thereof, are provided for use in the treatment and/or prophylaxis of a condition selected from macular oedema, conditions causing damage to retinal photoreceptors and/or retinal pigment epithelial cells, and dry eyes in a mammal, wherein the combined dosage of eicosapentaenoic acid and docosahexaenoic acid is from 5 mmol to 25 mmol per day, and wherein the molar ratio of eicosapentaenoic acid to docosahexaenoic acid is in the range of from 1:1 to 5:1. Compositions comprising epa and dha and at least one pharmaceutically acceptable excipient, and kits containing epa, dha and further therapeutic agents are also provided.
|Inhibition of cell proliferation|
The disclosed modulators of rb:raf-1 interactions are potent, selective disruptors of rb:raf-1 binding, with ic50 values ranging from 80 nm to 500 nm. Further, these compounds are surprisingly effective in inhibiting a wide variety of cancer cells, including osteosarcoma, epithelial lung carcinoma, non-small cell lung carcinoma, three different pancreatic cancer cell lines, two different glioblastoma cell lines, metastatic breast cancer, melanoma, and prostate cancer.
|Method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm|
The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, ef-i-delta, or m2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.. .
|Targeting p63 to re-activate dormant reserve stem cells in olfactory epithelium|
Disclosed herein is a method for activating a dormant epithelial stem cell, or population thereof, to a state of multipotency comprising, reducing the level of Δnp63 in the cell(s). The dormant epithelial stem cell(s) may be a horizontal basal cell (hbc) of the olfactory epithelium and the level of Δnp63 may be reduced by contacting the cell or population with an effective amount of one or more agents that downmodulate Δnp63.
|Ectocornea-like sheet and method of constructing the same|
It is intended to provide a transplantation material applicable to ocular surface diseases with a need for ectocornea transplantation (i.e., an ectocornea-like sheet). Oral mucosal epithelial cells are inoculated onto an amnion and then cultured in the coexistence of supporter cells.
|Biomarkers for epithelial cancer diagnosis and treatment|
Disclosed herein are methods for diagnosing the state of an epithelial tumor or tissue in a subject. Also disclosed are methods of diagnosing tumor initiation in an epithelial tissue of a subject.
|Compositions and methods for enhancing drug delivery across and into epithelial tissues|
This invention provides compositions and methods for enhancing delivery of drugs and other agents across epithelial tissues, including the skin, gastrointestinal tract, pulmonary epithelium, ocular tissues and the like. The compositions and methods are also useful for delivery across endothelial tissues, including the blood brain barrier.
|Method of isolating human neuroepithelial precursor cells from human fetal tissue|
A method for isolating human neuroepithelial precursor cells from human fetal tissue by culturing the human fetal cells in fibroblast growth factor and chick embryo extract and immunodepleting from the cultured human fetal cells any cells expressing a2b5, ng2 and encam is provided. In addition, methods for transplanting these cells into an animal are provided.
|Esophageal cancer markers|
The present invention is directed to methods for diagnosing cancer in a subject. Morphologically normal epithelial cells of the esophagus are assayed for marker expression.
|Modification of root form dental implants for accelerated tissue regeneration|
An endosseous dental implant for guided regeneration of gingival tissue onto the implant and method of producing the same is prepared by coating a region of the implant with biocompatible, random or aligned microfibers or nanofibers to which gingival epithelial and connective tissue cells may become attached. The fibers may be degradable or nondegradable.
|Strain of l. bulgaricus capable of inhibiting the adhesion of h. pylori strains to epithelial cells|
The present invention relates to a new strain of lactobacillus delbrueckii subsp. Bulgaricus, suitable for use in the treatment or prevention of helicobacter pylori infection..
|Compositions derived from stem cell released molecules & methods for formulation thereof|
Compositions for use in treatment of a variety of tissue diseases include stem cells and stem cell released molecules (srm's) suspended in an aqueous solution with a cellulosic material or other thickening agent. The stem cells and srm's can be derived from one or more distinct cell lines.
|Canceration information providing method and canceration information providing device|
There is provided a canceration information providing method which can detect the possibility of cancer in the initial stage with high accuracy. The canceration information providing method for providing information pertaining to canceration of cells includes: acquiring measurement data including first data pertaining to size of a cell nucleus and second data pertaining to size of a cytoplasm for each cell contained in a measurement sample which includes cells collected from epithelial tissue; extracting the measurement data of cells to be analyzed, which are at least some of the cells located toward the basal membrane side of the cells existing in the surface layer in the epithelial tissue, from the measurement data of a plurality of cells in the measurement sample based on the first data and the second data acquired for each cell; and analyzing the extracted measurement data and outputting the information pertaining to the canceration of cells..
|Cardiac glycosides to treat cystic fibrosis and other il-8 dependent disorders|
Disclosed is the use of a cardiac glycoside to decrease or inhibit the secretion of proinflammatory mediators in the treatment of disease conditions characterized by elevated levels of the proinflammatory mediator. The cardiac glycoside is administered to a mammalian subject in need of such treatment, and dosage is adjusted to the mass of the recipient and the need of the recipient to reduce or inhibit the level of the proinflammatory mediator.
|Methods and compositions for the diagnosis and treatment of epithelial cancers|
Methods for detecting, diagnosing and monitoring an epithelial cancer in a patient are described comprising measuring in a sample from the patient ep-icd polypeptides and ep-icd polynucleotides. Methods for prognosis of breast cancer comprising measurement of nuclear ep-icd polypeptides and optionally epex polypeptides are provided.
|Molecular analysis of tumor samples|
This invention relates to methods for diagnosing cancer, e.g., cancer of epithelial origin, by detecting the presence of tumor cells in a sample, based (at least in some embodiments) on the quantification of levels of four biomarkers, muc1, egfr, epcam, and her2. In some embodiments, the methods are performed using diagnostic magnetic resonance (dmr), e.g., with a portable relaxometer or mr imager..
|Integrated assay that combines flow-cytometry and multiplexed hpv genotype identification|
A two part assay is disclosed that enables collection of both protein biomarker phenotype and specific hpv genotype data from within a clinically derived population of cervical epithelial cells. Presence of multiple transformation-associated protein biomarkers acts as a gating criterion for cell sorting, followed by application of a pcr protocol sensitive enough to detect and identify individual hpv types from within the cells captured during sorting.
|Nucleic acid composition and methods of eliciting an immune response using the same|
The present invention provides for novel compositions and methods for delivering genes of interest to stem cells using vectors that contain differentiation-specific transcriptional regulatory elements. For example, stem cells in the internal epithelia could be transfected with a vaccine construct, which has an epithelial cell differentiation-specific promoter driving the expression of viral envelope proteins.
|Vacuum cast ("vac-cast") and methods for treatment of plantar wounds|
A combination of four wound care products include (1) a wound vacuum dressing providing a more sterile cover over the wound to prevent infection, provide a closed system to prevent maceration and soiling from drainage to the surrounding skin and peg insole pad, to introduce and maintain negative pressure, to decrease excessive fluid to the wound(s) and provide an environment to increase granulation and epithelialization; (2) a compression hose for additional support to the lower leg, ankle, and foot, aiding in proper fluid pressure control in the lower extremity and protects against friction of the contact cast against the lower extremity; (3) a removable peg insole foot insert offloading pressure and friction from the wound as well as providing a pressure free pathway to the ankle connection point which prevents obstruction, and (4) a total contact cast with inner padding layer to further off load pressure from the wound(s).. .
|Methods and compositions for treatment of epithelial wounds|
This invention relates to treatment of epithelial wounds. In particular, the invention relates to methods and formulations for treating epithelial wounds based on application of an opioid antagonist such as naltrexone..
|Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity|
And their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.. .
|Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives|
In free or salt or solvate form, where r1, r2, r3, r4, r5, r6, r7, r8, r9, r10 and r11 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described..
|Gleason grading by segmenting and combining co-registered images of differently stained tissue slices|
An improved histopathological score is obtained by generating image objects from images of tissue containing stained epithelial cells. First objects are generated that correspond to basal cells stained with a first stain, such as p63.
|Medical dressing for respiratory epithelial cells|
The present invention provides a medical dressing for respiratory epithelial cells comprising a biocompatible polymer and retinoic acid, wherein, based on total volume of the dressing, the polymer is 99% or more, and retinoic acid is 1% or less.. .
|Methods for generating predictive models for epithelial ovarian cancer and methods for identifying eoc|
A method for generating a model for epithelial ovarian cancer is presented, comprising the steps of obtaining a mass spectrum for each of a plurality of samples, segmenting each of the mass spectra into “bins,” and determining a plurality of relationships between two or more bins. One are more statistically significant factors are identified according to the determined plurality of relationships, and a predictive model is generated as a function of the one or more identified factors.
|Method of relieving, improving, preventing or treating xerostomia|
Provided is a method of relieving, improving, preventing or treating xerostomia including applying an oral cavity composition including a polyethylene glycol (peg) derivative whose reactor is modified to form a covalent bond with an epithelial cell of the oral cavity. An oral moisturizing effect and moisture persistency are increased and the method is effective against xerostomia due to aging or disease..
|Emt signatures and predictive markers and method of using the same|
Emt signatures and markers useful for characterizing the status of epithelial cancers and for predicting drug responses in patients having non-small cell lung cancer are provided together with methods of using the same.. .
|Method of preventing or reducing scarring of human skin|
Insulin or a peroxisome proliferator-activated receptor (ppar) agonist provides reliable and effective prevention of scarring in human skin, or at least a reduction in the severity of scarring. The application of insulin or the ppar agonist to wounds topically or by local injection is particularly advantageous since it simultaneously reduces/prevents scarring whilst enhancing re-epithelialisation of the wound and thus provides a dual action wound healing treatment.
|Micro organ comprising mesenchymal and epithelial cells|
The invention provides a micro-organ composite which comprises a core group of cells and an outer layer of cells, wherein the cells of the core group are mesenchymal cells and the cells of the outer layer are epithelial cells or wherein the cells of the core group are epithelial cells and the cells of the outer layer are mesenchymal cells, and wherein the core group of cells is at least partially encapsulated by the outer layer of cells.. .
|Mesenchymal stem cells and uses therefor|
Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, repairing epithelial damage and promoting angiogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.. .
|Thermal induced necrosis of lens epithelial cells|
Lens epithelial cells are destroyed and further growth is inhibited coincidental with eye surgery such as cataract surgery by heating the cells to a temperature above normal to thereby destroy the cells and inhibit future growth. The cells are heated by placement of a thermally conductive ring within the lens capsule and heating the ring thereby raising the temperature of lens epithelial cells adjacent to the ring..
|Re-epithelialization wound dressings and systems|
Methods, apparatuses, and systems for promoting re-epithelialization as an aspect of wound healing are presented. A re-epithelialization dressing for use with reduced pressure has a moist tissue-interface layer, a manifold member, and a sealing member.
|Methods for forming normal regenerated tissues, the normal regenerated tissues and methods for assessing sensitivities and so on|
A normal regenerated tissue is formed by exposing to radiation a connective tissue or a supporting tissue originating in an organ to thereby form a feeder layer and then transplanting epithelial cells thereon to form a stratified structure. By conveniently and surely providing regenerated tissue by the 3-dimensional culture with the use of a human-origin normal tissue as a base, it is possible to construct systems for assessing effects and side effects of chemicals such as drugs or assessing sensitivities thereof with the use of regenerated tissues as models of corresponding tissues respectively..
|Artificial tissue constructs comprising alveolar cells and methods for using the same|
The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung.